The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification
Hose Dirk, Seckinger Anja, Jauch Anna, Reme Thierry, Moreaux Jerome, Bertsch Uta, Neben Kai, Klein Bernard, Goldschmidt Hartmut
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):84-89
Details  Full text ( 183 KB)  DOI:10.2298/SARH11S2084H
Timing of the high-dose therapy in the area of new drugs
Schmitt Stefan, Bertsch Uta, Hose Dirk, Goldschmidt Hartmut
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):90-94
Details  Full text ( 174 KB)  DOI:10.2298/SARH11S2090S
Updated criteria for diagnosis and risk stratification in patients with multiple myeloma
Đurđević Predrag, Anđelković Nebojša, Bila Jelena
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):95-102
Details  Full text ( 221 KB)  DOI:10.2298/SARH11S2095D
Induction therapy and the role of stem cell transplantation in the treatment of myeloma multiplex in patients aged below 65 years
Stamatović Dragana, Tukić Ljiljana, Balint Bela
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):103-109
Details  Full text ( 219 KB)  DOI:10.2298/SARH11S2103S
New concept of the treatment in elderly patients with multiple myeloma
Bila Jelena, Gotić Mirjana, Mihaljević Biljana
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):110-115
Details  Full text ( 201 KB)  DOI:10.2298/SARH11S2110B
Clinical efficacy of novel therapeutic combinations in the treatment of patients with relapsed or refractory myeloma
Savić Ivanka, Popović Stevan
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):116-121
Details  Full text ( 202 KB)  DOI:10.2298/SARH11S2116S
Current approaches to supportive care in multiple myeloma
Govedarović Nenad, Vukićević Tomislav
Srpski arhiv za celokupno lekarstvo, 2011 139(suppl. 2):123-128
Details  Full text ( 187 KB)  DOI:10.2298/SARH11S2123G